<DOC>
	<DOCNO>NCT00004412</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare efficacy local care alone vs local care plus arginine butyrate term heal rate patient refractory sickle cell ulcer . II . Determine effect arginine butyrate therapy tissue factor related promotion inhibition wound heal patient . III . Determine whether regimen use study appropriate test pivotal trial .</brief_summary>
	<brief_title>Phase II Randomized Trial : Arginine Butyrate Plus Standard Local Therapy Patients With Refractory Sickle Cell Ulcers</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive arginine butyrate IV 6-9 hour night 5 day week 12 week , plus concurrent standard local therapy consist cleaning , saline irrigation , dress change prescribe patient 's physician . Patients experience progressive healing receive arginine butyrate 3-4 time week . Arginine butyrate treatment may discontinue reinstate follow single 2 week medical complication . Arm II : Patients receive standard local therapy alone 12 week . Patients randomize arm II may cross receive arginine butyrate le 25 % heal observe 12 week . Patients whose ulcer close least 15 % per cycle may receive 2 additional 8-week cycle arginine butyrate therapy follow 2 month heal complete .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<mesh_term>Arginine butyrate</mesh_term>
	<criteria>PROTOCOL CRITERIA INCLUSION : Disease Characteristics Significant sickle cell syndrome include Hemoglobin SS ( HbSS ) , Hemoglobin Sbeta thalassemia , hemoglobin variant . Lower extremity ankle ulcer ( ulcer ) present least 6 month without heal Patient Characteristics Age : 1660 yr Performance status : Not specify Hematopoietic : Not specify Hepatic : No hepatic compromise Transaminases great 250 IU Renal : No renal compromise Creatinine great 1.2 mg/mL ( adult ) Creatinine great 0.9 mg/mL ( teenager ) Other : Not pregnant Fertile patient must use effective contraception No poorly control seizure disorder No secondary condition might inhibit immune function Prior/Concurrent Therapy Other : Must treat antibiotic prior entry complicate cellulitis secondary infection EXCLUSION : Prior/Concurrent Therapy Biologic therapy : chronic transfusion therapy Chemotherapy : prior concurrent cancer chemotherapy concurrent butyrate derivative Endocrine therapy : concurrent corticosteroid therapy Radiotherapy : Not specify Surgery : Not specify Patient Characteristics Hepatic : hepatic compromise Transaminases great 250 IU Renal : renal compromise Creatinine great 1.2 mg/mL ( adult ) Creatinine great 0.9 mg/mL ( teenager ) Other : pregnant ; Fertile patient effective contraception Poorly control seizure disorder secondary condition might inhibit immune function</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>dermatologic disorder</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>skin ulcer</keyword>
	<keyword>thalassemia major</keyword>
</DOC>